Close Menu

Webinar/Video Library


In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program. 

Increases in sequencing power, laboratory automation, and bioinformatics have revolutionized agriculture genomics, but until the rise of the DRAGEN system, computing was the biggest roadblock for Dr. Johnson’s team. He will discuss how the platform has enabled his lab to reduce post-run data processing time from days to hours and in some cases minutes.

Dr. Johnson will also share how his team has expanded use of the DRAGEN system across the whole analysis pipeline, describe areas where the power of the platform’s hardware acceleration provides the best performance, and outline work being done to further improve efficiency.

Illumina’s Stephanie Black will review the DRAGEN technology, discuss key application areas, summarize recent advancements, and walk through the growing DRAGEN access points, both on-premises and in the cloud.

Sponsored by
Partner Webinar

In this webinar, you will discover the power of HGMD Professional and see why reference labs around the world, such as LabCorp and Genomics England, use HGMD Professional in their clinical test interpretation. Through a live demonstration, you will learn how to use the online interface and downloadable database, as well as how to use HGMD Professional and ANNOVAR to produce a powerful in-house variant interpretation solution.

Sponsored by
Partner Webinar

The remarkable advances in precision medicine are unfortunately not currently available to all patients, especially those being treated in community cancer settings. This growing “gap” is now challenging the health system to provide cost-effective, scalable, innovative solutions for underserved patients. Protean BioDiagnostics was founded to close this gap and accelerate access to precision oncology for all patients, regardless of where they live. To this end, Protean has created an adaptable and innovative framework for rapidly deploying the latest companion diagnostics. Protean’s simplification of universal access to complex diagnostics is poised to change the practice of precision oncology in the community and truly “close the gap.”

In this webinar, you will learn more about

  1. Protean’s proprietary, multi-omic, data-centric Oncology MAPS™ system and how the system creates an easy way for oncologists and patients to access the latest evidence-based diagnostics, guideline-driven therapeutics, and new clinical trials.
  2. How QIAGEN’s bioinformatics team and Protean are working together to successfully deploy WES into clinical practice and give practitioners the knowledge to improve disease risk management and select treatment.
  3. Protean’s goal of maintaining and managing genetic and other medical data for patients in MAPS™ system, which enables this complex genetic data to become both “future-protected” and an enduring legacy for the patient, and their family.
Sponsored by

Founder and CEO,
Blackhawk Genomics

This webinar discusses the opportunity for clinical laboratories to implement efficient tertiary analysis pipelines and share best practices for selecting and implementing a tertiary analysis pipeline for variant interpretation.

Clinical laboratories are rapidly expanding both the scope and complexity of hereditary services offered utilizing next-generation sequencing. With this expansion come a significant number of challenges including turnaround time, the need for specialized clinical genetic knowledge and overall scalability. Adopting a thoughtful strategy for selection and implementation of appropriate tertiary analysis tools is critical to the success of a clinical NGS program.

In this educational webinar, Dr. Tootie Tatum of Blackhawk Genomics will discuss the following:

  • Market trends and opportunities for clinical laboratories performing hereditary NGS
  • Current challenges in NGS interpretation and ways to overcome them
  • Propose strategies to introduce NGS into the laboratory
  • Aligning the capabilities of variant interpretation solutions with laboratory resources
  • The importance of depth, breadth and completeness of quality variant interpretation content
Sponsored by

Research Scientist, Experimental Pathology; Division of Advanced Research Technologies, New York Langone Medical Center

An increasing number of technologies combine spatial discrimination with molecule identification, as has been done for decades through immunohistochemistry and in situ hybridization. The difference is that now a range of commercially available platforms promises to significantly increase the number of targets that can be identified on a single sample. These platforms also provide higher throughput in terms of the number of samples that can be interrogated, and some offer semi-automation with straightforward sample preparation.

These characteristics promise to make the new spatial profiling technologies attractive candidates for biomedical research facilities, but in order to discriminate between them, it is necessary to share real-world experiences using them in core labs.

This session will share the experience at New York University Langone Health using Nanostring’s GeoMx digital spatial profiling platform as a service for research laboratories. Dr. Valeria Mezzano of NYU Langone will discuss how her team approaches each project, interacts with clinical researchers, and performs the assays as an integrated network of core facilities.

Sponsored by

Global Head, Illumina Accelerator

Co-founder & CEO, Biome Makers

Co-founder & CEO, Juno Bio

CEO, BioAmp

Co-Founder and Chief Operating Officer, 4baseCare

The decreasing cost of genomic technologies has democratized their use for many biotech and clinical breakthrough applications. Entrepreneurs are playing a key role in advancing these applications by translating scientific breakthroughs and ideas into commercially viable businesses that transcend borders.

Join the Illumina Accelerator and four global genomics startups in the biotech, clinical, and agricultural industries to discuss key trends in entrepreneurship; how to build a genomics startup from ideation to commercialization; how to access capital; and how to navigate and find opportunity in the current challenging climate.

Sponsored by

Application Scientist,

Chief Science Officer,
OnRamp Bio 

Epigenetic regulators are constituted by a great diversity of subunits, which are often redundant to varying extents. Novel experimental strategies including genome editing and small molecule-inducible systems allow for systematic dissection of multi-subunit complexes. While these approaches are ideal to assess the transcriptional consequences of combinatorial genetic perturbations to epigenetic pathways, the sequencing costs associated with gene expression analysis by RNA-seq quickly escalate as a function of sample number.

Lexogen QuantSeq facilitates increased multiplexing capacity without ramping up the sequencing costs by focusing on the 3’ ends of mRNAs. Such gene expression profiling approaches require only about 10 percent of sequencing depth compared to standard RNA-seq methods.

In this webinar, Jorge Zepeda from Lexogen will discuss a study conducted at the Institute of Molecular Biotechnology that used small molecule-inducible genetic perturbations in combination with transcriptional profiling by QuantSeq and chromatin immunoprecipitation sequencing (ChIP-seq) analysis to unravel the differential subunit requirements of polycomb repressive complexes 1 (PRC1) and 2 (PRC2), in maintaining robust silencing of lineage-specific genes and self-renewal capacity in mouse embryonic stem cells.

The second speaker, Jean Lozach from OnRamp Bio will demonstrate the capabilities of the OnRamp Bioinformatics discovery platform Rosalind to analyze and integrate multi-omics datasets like the QuantSeq and ChIP-seq used in this study and, will also show a new option for efficient collaboration between researchers.

Sponsored by

Associate Professor,
Department of Integrative Biology & Centre for Biodiversity Genomics, University of Guelph

All living organisms shed DNA into their environment, and these traces of DNA can now be profiled using next-generation sequencing. Thanks to a colossal effort around the world to sequence the molecular markers (e.g. DNA barcodes) of hundreds of thousands of eukaryotic species, we now have databases that allow us to match eDNA to its sources. By using the massive capacity of high-throughput sequencers, we can now survey the presence and dynamics of shifts in biodiversity in different environments and monitor it over time. 

Existing methods for environmental surveys are costly and time consuming, often relying on invasive or destructive sampling methods, and specialist expertise from taxonomists to correctly identify species. Metabarcoding promises to be a complementary alternative that will enable researchers, governments, and industry to gain more comprehensive insights into changes in biodiversity, and make more informed choices around conservation, environmental impact assessment, water quality monitoring, biosecurity, and more. 

This webinar will review recent research and validation experiments demonstrating the power of metabarcoding for a range of potential applications. 

Attendees of this webinar will learn about: 

  • Biodiversity markers and DNA barcoding
  • Metabarcoding and environmental DNA
  • Sample types and sampling regimes
  • Next-generation sequencing approaches for eDNA metabarcoding
  • Bioinformatics for taxonomic assignment and validation
  • Experimental design aspects from sample to data analysis and interpretation
  • Freshwater metabarcoding for water quality assessment
  • Soil metabarcoding for ecological surveys
  • Comprehensive biodiversity assessment in seawater using ultra-deep metabarcoding
Sponsored by

Vice President, Associate Dean, University of South Florida and Executive Medical Director,
Access to Expanded Carrier Screening Coalition

Advances in DNA sequencing technology have dramatically enhanced our ability to perform more comprehensive genetic risk assessments. Carrier screening protocols for the detection of serious and prevalent inheritable disorders have seen significant evidence-based advances but have experienced slow adoption, limited primarily by education of pregnant women and providers.  

Population demographics and variability in population ethnicity have redefined a couple’s risk for many inheritable autosomal recessive disorders. Advances like next-generation sequencing and sophisticated bioinformatics pipelines have provided insight into carrier frequencies in more diverse populations and identified the gaps that are created by current guidelines.

This webinar is the first in a three part series that will present cases that highlight the benefits of expanded carrier screening research for less well known inheritable conditions.

Join Dr. Brown in this webinar to learn about:

  • The evolution of expanded carrier screening  
  • Current guidelines and their role 
  • Cases highlighting the power of expanded carrier screening  
Sponsored by

Research Assistant,
National Institute of Biology

Director of Molecular Biology R&D,
Stilla Technologies

The commercialization of digital PCR platforms has sparked a revolution in quantitative nucleic acid detection over the past decade. Stilla Technologies’ Naica System, an established easy-to-use digital PCR platform, offers an innovative solution that quantifies in three colors while minimizing time to results.  

This webinar will present the features of the company’s new 6-color Crystal Digital PCR System and highlight a set of applications poised to greatly benefit from the increased multiplexing and high sensitivity of 6-color digital PCR. 

First, Alexandra Bogozalec from the National Institute of Biology in Slovenia will detail how her team has capitalized on the high-plex capacity of 6-color Crystal Digital PCR to simplify the time-consuming GMO quantification workflow and simultaneously quantify a set of genetically modified soybean lines at low target concentrations.  

This webinar will also discuss how the highly sensitive detection capability of 6-color Crystal Digital PCR benefits oncology applications. Allison Mallory of Stilla Technologies will present high-plex mutation detection in non-small cell lung cancer, colorectal and breast cancer samples and will show how 6-color digital PCR enables efficient therapeutic monitoring and early detection of treatment resistance through noninvasive liquid biopsy. 

Sponsored by

Professor, Division of Cellular Immunology, La Jolla Institute for Allergy and Immunology & Head of Cancer Vaccines, Human Longevity Inc.

Medical Oncologist & Assistant Professor of Medicine, UC San Diego Health


T-cell receptor (TCR) therapy is a rapidly emerging adaptive cell therapy (ACT) method in the field of cancer immunotherapy. However, the process for developing effective T-cell receptors can be time consuming, particularly with regard to the rigorous functional testing needed prior to scale-up and patient infusion.

In this webinar, Stephen Schoenberger of the La Jolla Institute for Immunology discusses how he is leveraging an automated DNA assembly and cloning platform, the BioXp 3200, to achieve a 10-fold increase in the development of TCRs.


Sponsored by
June 10, 2020
Sponsored by
Advanced Cell Diagnostics

Viral Pathogenesis Research: Molecular Detection with RNAscope

Partner Webinar

Direct detection of viral RNA in human or other animal cells by RNA in situ Hybridization (ISH) is a powerful tool to establish the etiology and pathogenesis of viral disease. Nucleic acid-based molecular detection methods have revolutionized viral detection, offering several essential advantages such as sensitivity, specificity, and speed.

Beyond this, RNAscope ISH uniquely offers molecular detection coupled with morphological context to enable visualization of the virus in different infected tissues and cell types.

In this webinar, we will demonstrate how RNAscope can be used to detect viral infection and pathogenesis, and enhance our understanding of globally important viruses, such as SARS-CoV-2.

Sponsored by

Technical Director, Clinical Genomics,
Providence Cancer Center

Staff Product Manager,

Senior Scientist,

Comprehensive genomic profiling (CGP) is becoming standard of care for cancer and allows pathology labs to consolidate individual biomarkers into a single NGS assay. It enables the assessment of all key biomarkers cited in guidelines and clinical trials using a minimal amount of formalin-fixed, paraffin-embedded (FFPE) tissue while increasing the chance of finding a positive biomarker for every sample. 

Illumina’s TruSight Oncology 500 High-Throughput (TSO500 HT)assay enables labs to perform in-house CGP with scalability on a NovaSeq 6000 platform. 

In this webinar, Brian Piening of Providence Cancer Center will discuss why his team decided to implement in-house CGP and will share analytical performance data from their TSO500_HT runs. He will also provide details of the center’s end-to-end workflow, including the data analysis flow and how they build their final reports.

Attendees of this webinar will learn about: 

  • Providence Cancer Center’s implementation of in-house CGP
  • Illumina’s solution enabling in-house CGP
Sponsored by

Professor for Molecular Hematology,
Medical Faculty Carl Gustav Carus, Technical University of Dresden

The invention of novel high-throughput technologies, especially next-generation sequencing (NGS), has spurred our understanding of the development of human cancers and opened new avenues for rapid and comprehensive diagnosis. Especially in hematological malignancies, the availability of these novel high-throughput technologies has greatly enhanced our capabilities for the identification of disease, defining lesions and targets for tailored treatment. At the same time, these diagnostic tools have inherent aspects that make them vulnerable to false positives as well as false negatives. Major aspects are balanced coverage, the rate of detection of long insertions and deletions, as well as the sensitivity of the assay. 

Besides these technical aspects, the comprehensive and adequate interpretation of results, especially in the light of more recent discoveries regarding preleukemic, clonal hematopoiesis, such as clonal hematopoiesis with indeterminate potential (CHIP), adds an additional layer of complexity, which requires a substantial level of expertise to avoid over- as well as underinterpretation of results.

Nevertheless, the important information gained by using NGS-based evaluation of patients for the presence of mutations enables much more comprehensive analysis; identification of disease-defining lesions (e.g., mutations in genes like NPM1, CEBPA, SETBP1); and potential targets for treatment (e.g., cKIT, FLT3) and risk stratification (e.g., TP53, RUNX1 or ASXL1).

In this webinar, Dr. Christian Thiede, Professor for Molecular Hematology at the Technical University of Dresden will discuss the pros and cons of these methods, their appropriate and cost-effective use, as well as aspects to keep in mind for data interpretation will be discussed.

For Research Only. Not for use in diagnostics procedures.

Sponsored by
June 04, 2020
Sponsored by

COVID-19 Testing, Treatment and Future Outlook


Chief Scientific Officer, Vikor Scientific

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Attendees of this webinar will learn about:

  • The role of PCR and antibody testing in the management of the pandemic;
  • The role of potential treatments for COVID-19 and future vaccines on the management of the pandemic;
  • Actions that need to be taken to mitigate the impact of future pandemics.
Sponsored by


The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

Interested in Posting your Webinar or White Paper on GenomeWeb?

Contact us